Exact Sciences (EXAS) Competitors $57.75 +0.12 (+0.21%) Closing price 04:00 PM EasternExtended Trading$57.86 +0.12 (+0.20%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. BIIB, UTHR, INCY, NBIX, EXEL, BMRN, IONS, MDGL, HALO, and RGENShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Its Competitors Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Ionis Pharmaceuticals Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Exact Sciences (NASDAQ:EXAS) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends. Do institutionals and insiders have more ownership in EXAS or BIIB? 88.8% of Exact Sciences shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 1.2% of Exact Sciences shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is EXAS or BIIB more profitable? Biogen has a net margin of 15.31% compared to Exact Sciences' net margin of -34.19%. Biogen's return on equity of 13.85% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Exact Sciences-34.19% -1.75% -0.76% Biogen 15.31%13.85%8.32% Which has stronger earnings & valuation, EXAS or BIIB? Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExact Sciences$2.94B3.72-$1.03B-$5.43-10.64Biogen$9.68B2.31$1.63B$10.4614.57 Does the media favor EXAS or BIIB? In the previous week, Biogen had 11 more articles in the media than Exact Sciences. MarketBeat recorded 17 mentions for Biogen and 6 mentions for Exact Sciences. Biogen's average media sentiment score of 1.05 beat Exact Sciences' score of 0.98 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exact Sciences 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 9 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, EXAS or BIIB? Exact Sciences has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500. Do analysts recommend EXAS or BIIB? Exact Sciences currently has a consensus price target of $68.71, indicating a potential upside of 18.91%. Biogen has a consensus price target of $180.04, indicating a potential upside of 18.12%. Given Exact Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Exact Sciences is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exact Sciences 1 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.83Biogen 1 Sell rating(s) 20 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.31 SummaryBiogen beats Exact Sciences on 9 of the 17 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.94B$3.32B$6.11B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-10.6421.6185.6926.92Price / Sales3.72424.41583.01184.15Price / Cash10.0746.3226.3031.10Price / Book4.4510.0613.246.71Net Income-$1.03B-$52.22M$3.30B$276.35M7 Day Performance5.62%5.87%4.64%3.10%1 Month Performance7.39%12.07%8.36%10.19%1 Year Performance-16.56%26.14%87.97%40.37% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.5131 of 5 stars$57.75+0.2%$68.71+19.0%-15.7%$10.93B$2.94B-10.647,000Positive NewsAnalyst ForecastBIIBBiogen4.5581 of 5 stars$138.52+0.8%$182.04+31.4%-17.0%$20.14B$9.68B13.247,605Positive NewsAnalyst ForecastUTHRUnited Therapeutics4.331 of 5 stars$424.31-1.9%$449.57+6.0%+27.4%$19.52B$2.88B16.561,305Insider TradeINCYIncyte4.5045 of 5 stars$83.89+1.4%$83.67-0.3%+29.2%$16.15B$4.24B19.072,617NBIXNeurocrine Biosciences4.7894 of 5 stars$140.27-1.2%$161.89+15.4%+22.3%$14.08B$2.36B41.501,800News CoverageEXELExelixis4.8387 of 5 stars$40.57+3.9%$44.42+9.5%+50.1%$10.51B$2.17B19.501,147Positive NewsBMRNBioMarin Pharmaceutical4.9514 of 5 stars$54.02+0.3%$92.60+71.4%-20.0%$10.34B$2.85B16.033,040IONSIonis Pharmaceuticals3.4121 of 5 stars$64.15+0.1%$73.88+15.2%+82.1%$10.22B$705M-34.861,069Analyst ForecastMDGLMadrigal Pharmaceuticals4.307 of 5 stars$443.10+4.4%$495.88+11.9%+112.2%$9.42B$180.13M-34.4890HALOHalozyme Therapeutics4.7145 of 5 stars$73.29-0.6%$69.89-4.6%+13.2%$8.63B$1.02B16.77390Analyst RevisionRGENRepligen4.6074 of 5 stars$124.09-1.2%$168.75+36.0%+9.8%$7.07B$634.44M-496.341,778Analyst Forecast Related Companies and Tools Related Companies Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Ionis Pharmaceuticals Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Repligen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
